propiverine has been researched along with Urinary Bladder, Overactive in 58 studies
propiverine: anticholinergic used for overactive bladder syndrome
Urinary Bladder, Overactive: Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of treatment with alfuzosin 10 mg plus propiverine 10 or 20 mg in men with lower urinary tract symptoms (LUTS) and an overactive bladder were investigated." | 9.19 | Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study. ( Cho, HJ; Cho, JM; Kang, JY; Moon, HS; Seo, DY; Shin, SC; Sung, LH; Yoo, TK; Yu, JH, 2014) |
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 9.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence." | 9.14 | Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. ( Feustel, C; Marschall-Kehrel, D; Persson de Geeter, C; Radmayr, C; Sillén, U; Stehr, M; Strugala, G, 2009) |
| "To compare, in a retrospective observational cohort study, the efficacy, tolerability and safety of propiverine and oxybutynin in children with urge incontinence (UI) due to overactive bladder." | 7.76 | Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Braun, R; Gerhardt, U; Heinrich, M; Hellmis, E; Horn, W; Madersbacher, H; Marschall-Kehrel, D; Mürtz, G; Niklas, K; Raabe, M; Rössler, T; Schultz-Lampel, D; Seibt, B; Siemer, S; Strugala, G; Walter, H; Wiedeking, B, 2010) |
| "Propiverine was generally well tolerated in these patient populations, with a lower incidence of dry mouth than that associated with oxybutynin." | 6.49 | Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. ( McKeage, K, 2013) |
| "The efficacy and safety of treatment with alfuzosin 10 mg plus propiverine 10 or 20 mg in men with lower urinary tract symptoms (LUTS) and an overactive bladder were investigated." | 5.19 | Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study. ( Cho, HJ; Cho, JM; Kang, JY; Moon, HS; Seo, DY; Shin, SC; Sung, LH; Yoo, TK; Yu, JH, 2014) |
| "To assess the efficacy and safety of propiverine hydrochloride (antimuscarinic), naftopidil (alpha(1)-adrenoceptor antagonist) or both in patients with male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia and concomitant overactive bladder (OAB)." | 5.14 | Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. ( Kumon, H; Nagai, A; Sasaki, K; Uematsu, K; Watanabe, T; Yokoyama, T, 2009) |
| "This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence." | 5.14 | Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. ( Feustel, C; Marschall-Kehrel, D; Persson de Geeter, C; Radmayr, C; Sillén, U; Stehr, M; Strugala, G, 2009) |
| "To compare, in a retrospective observational cohort study, the efficacy, tolerability and safety of propiverine and oxybutynin in children with urge incontinence (UI) due to overactive bladder." | 3.76 | Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Braun, R; Gerhardt, U; Heinrich, M; Hellmis, E; Horn, W; Madersbacher, H; Marschall-Kehrel, D; Mürtz, G; Niklas, K; Raabe, M; Rössler, T; Schultz-Lampel, D; Seibt, B; Siemer, S; Strugala, G; Walter, H; Wiedeking, B, 2010) |
| " CV safety was assessed using treatment-emergent adverse events (TEAEs), vital signs, and 12-lead electrocardiograms (ECGs)." | 2.94 | Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. ( Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O, 2020) |
| "1% women, mean age 65 years) experienced at least one treatment-emergent adverse event, with similar rates for all treatments." | 2.90 | Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). ( Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019) |
| "Propiverine ER 30 mg was confirmed to be an effective and well-tolerated treatment option for patients with OAB symptoms." | 2.84 | Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder. ( Du, C; Fang, Z; Feustel, C; Han, S; Leng, J; Li, W; Liao, L; Ma, L; Madersbacher, H; Shen, Z; Wan, B; Wu, S; Xie, K; Xu, Z; Yang, Y, 2017) |
| "Imidafenacin was not inferior to propiverine for the reduction of UUI episodes, and was better tolerated than propiverine in the safety profile." | 2.79 | A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder. ( Choo, MS; Kim, DY; Kim, JC; Lee, JG; Lee, JZ; Lee, KS; Lee, SJ; Park, C; Park, J; Seo, JT, 2014) |
| " Higher doses did not result in additional dose-proportional increases in the respective pharmacokinetic parameters, particularly not after repeated-dose treatment." | 2.75 | Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder. ( Feustel, C; Läckgren, G; Mürtz, G; Schnabel, F; Siegmund, W; Sillén, U, 2010) |
| "Imidafenacin was well tolerated." | 2.74 | A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder. ( Homma, Y; Yamaguchi, O, 2009) |
| "or oxybutynin 5mg t." | 2.73 | Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. ( Arnold, EP; Kramer, G; Mürtz, G; Schnabel, F; Stöhrer, M; Wyndaele, JJ, 2007) |
| "Storage/filling symptoms caused by overactive bladder (OAB) are bothersome to patients." | 2.73 | [Does alpha1-blocker provide additional improvement of quality-of-life in patients with overactive bladder?--a multi-center prospective randomized trial between anti-cholinergic (propiverine chloride) with and without alpha1-blocker (urapidil)]. ( Hara, Y; Harada, N; Imoto, K; Joko, K; Kamiryo, Y; Kaneda, Y; Matsuyama, H; Naito, K; Shimabukuro, T; Shimizu, Y; Suga, A; Takemoto, M; Yamamoto, N, 2007) |
| "04) and any adverse events (OR 0." | 2.52 | Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. ( Huang, W; Zhang, Y; Zhou, X; Zong, H, 2015) |
| "Propiverine was generally well tolerated in these patient populations, with a lower incidence of dry mouth than that associated with oxybutynin." | 2.49 | Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. ( McKeage, K, 2013) |
| "Propiverine was at least as effective as oxybutynin but with a better tolerability profile even in the pediatric setting." | 2.48 | An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. ( Artibani, W; Asimakopoulos, AD; Carone, R; Cerruto, MA; Del Popolo, G; Finazzi-Agrò, E; La Martina, M, 2012) |
| " The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)." | 2.48 | Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. ( Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012) |
| "This is usually due to overactive bladder syndrome (defined as urgency, with or without urge incontinence, and usually with frequency and nocturia), which occurs in around 12% of adults, and is similarly prevalent in men and women." | 2.44 | Update on drugs for overactive bladder syndrome. ( , 2007) |
| "The mean overactive bladder symptom score of these patients was 6." | 1.40 | Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. ( Akino, H; Fujiuchi, Y; Fuse, H; Kitagawa, Y; Miyazawa, K; Namiki, M; Suzuki, K; Yokoyama, O, 2014) |
| "Propiverine monotherapy was well tolerated in 11/17 patients." | 1.38 | Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. ( Austin, P; Heine, G; Knispel, HH; Michael, T; Miller, K; Mürtz, G; Schulte-Baukloh, H; Strugala, G, 2012) |
| "Propiverine was better tolerated than oxybutynin, having fewer adverse drug reactions (9." | 1.35 | Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study. ( Alloussi, S; Bock, P; Domurath, B; Henne, T; Körner, I; Madersbacher, H; Mürtz, G; Niedeggen, A; Nounla, J; Pannek, J; Schulte-Baukloh, H; Schultz-Lampel, D; Strugala, G, 2009) |
| "All of the male patients had benign prostatic hyperplasia (BPH), and all of the female patients had overactive bladder (OAB)." | 1.35 | Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder. ( Kadekawa, K; Miyazato, M; Mukouyama, H; Nishijima, S; Sugaya, K, 2009) |
| " The incidence of adverse events was 23." | 1.35 | [Efficacy and safety of propiverine on improvement of symptoms and QOL for female patients with wet overactive bladder]. ( Gotoh, M; Hattori, R; Kato, K; Kato, M; Kondo, A; Matsukawa, Y; Yamada, S, 2008) |
| "5%) of adverse events evidences a favourable risk-benefit profile of propiverine hydrochloride, considering in particular the total documented treatment and surveillance period of 171 patient years and nine months." | 1.33 | Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study. ( Goepel, M; Grigoleit, U; Kramer, G; Laschke, S; Mürtz, G; Schuldt, M; Stöhrer, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 25 (43.10) | 29.6817 |
| 2010's | 31 (53.45) | 24.3611 |
| 2020's | 2 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Müderrisoglu, AE | 1 |
| Oelke, M | 2 |
| Schneider, T | 1 |
| Murgas, S | 3 |
| de la Rosette, JJMCH | 1 |
| Michel, MC | 3 |
| Katoh, T | 1 |
| Igawa, Y | 2 |
| Yamaguchi, O | 5 |
| Kato, D | 1 |
| Hamada, T | 2 |
| Kuroishi, K | 2 |
| Nazir, J | 1 |
| Kelleher, C | 1 |
| Aballéa, S | 1 |
| Maman, K | 1 |
| Hakimi, Z | 1 |
| Mankowski, C | 1 |
| Odeyemi, I | 1 |
| Masumori, N | 1 |
| Funato, Y | 1 |
| Yamaguchi, Y | 1 |
| Itoh, K | 1 |
| Kakizaki, H | 2 |
| Homma, Y | 3 |
| Takeda, M | 1 |
| Nishizawa, O | 3 |
| Gotoh, M | 6 |
| Yoshida, M | 2 |
| Yokoyama, O | 5 |
| Seki, N | 2 |
| Okitsu, A | 1 |
| Kobayashi, A | 1 |
| Herbison, P | 1 |
| McKenzie, JE | 1 |
| Cetinel, B | 1 |
| Onal, B | 1 |
| Gultekin, MH | 1 |
| Guzelsoy, M | 1 |
| Turegun, FA | 1 |
| Dincer, M | 1 |
| Akino, H | 2 |
| Namiki, M | 1 |
| Suzuki, K | 2 |
| Fuse, H | 1 |
| Kitagawa, Y | 1 |
| Miyazawa, K | 1 |
| Fujiuchi, Y | 1 |
| Uchida, E | 1 |
| Higo, N | 1 |
| Minami, H | 1 |
| Kobayashi, S | 1 |
| Sato, H | 1 |
| Park, C | 1 |
| Park, J | 1 |
| Choo, MS | 2 |
| Kim, JC | 1 |
| Lee, JG | 2 |
| Lee, JZ | 2 |
| Lee, KS | 2 |
| Kim, DY | 1 |
| Lee, SJ | 1 |
| Seo, JT | 2 |
| Cho, HJ | 1 |
| Shin, SC | 1 |
| Seo, DY | 1 |
| Cho, JM | 1 |
| Kang, JY | 1 |
| Yoo, TK | 1 |
| Yu, JH | 1 |
| Sung, LH | 1 |
| Moon, HS | 2 |
| Huang, W | 1 |
| Zong, H | 1 |
| Zhou, X | 1 |
| Zhang, Y | 1 |
| Matsukawa, Y | 2 |
| Takai, S | 1 |
| Funahashi, Y | 1 |
| Kato, M | 2 |
| Yamamoto, T | 2 |
| Leng, J | 1 |
| Liao, L | 1 |
| Wan, B | 1 |
| Du, C | 1 |
| Li, W | 1 |
| Xie, K | 1 |
| Shen, Z | 1 |
| Xu, Z | 1 |
| Wu, S | 1 |
| Fang, Z | 1 |
| Ma, L | 1 |
| Han, S | 1 |
| Feustel, C | 3 |
| Yang, Y | 1 |
| Madersbacher, H | 4 |
| Sakakibara, F | 1 |
| Takahama, K | 1 |
| Nanri, M | 1 |
| Sasaki, E | 1 |
| Mürtz, G | 7 |
| Alloussi, S | 3 |
| Domurath, B | 1 |
| Henne, T | 1 |
| Körner, I | 1 |
| Niedeggen, A | 1 |
| Nounla, J | 1 |
| Pannek, J | 1 |
| Schulte-Baukloh, H | 2 |
| Schultz-Lampel, D | 2 |
| Bock, P | 2 |
| Strugala, G | 5 |
| Ates, F | 1 |
| Akyol, I | 1 |
| Cirakoglu, A | 1 |
| Yokoyama, T | 1 |
| Uematsu, K | 1 |
| Watanabe, T | 1 |
| Sasaki, K | 1 |
| Kumon, H | 1 |
| Nagai, A | 1 |
| Sakakibara, R | 1 |
| Ogata, T | 1 |
| Uchiyama, T | 1 |
| Kishi, M | 1 |
| Ogawa, E | 1 |
| Isaka, S | 1 |
| Yuasa, J | 1 |
| Ito, T | 1 |
| Yamanishi, T | 1 |
| Awa, Y | 1 |
| Yamaguchi, C | 1 |
| Takahashi, O | 1 |
| Kessler-Zumpe, PL | 1 |
| Neumann, G | 1 |
| Richter, AE | 1 |
| Sugaya, K | 3 |
| Nishijima, S | 3 |
| Kadekawa, K | 3 |
| Miyazato, M | 2 |
| Mukouyama, H | 1 |
| Lee, HW | 1 |
| Paick, JS | 1 |
| Lee, YS | 1 |
| Yoon, H | 1 |
| Park, CH | 1 |
| Na, YG | 1 |
| Jeong, YB | 1 |
| Lee, JB | 1 |
| Park, WH | 1 |
| Braun, R | 1 |
| Gerhardt, U | 1 |
| Heinrich, M | 1 |
| Hellmis, E | 1 |
| Horn, W | 1 |
| Marschall-Kehrel, D | 2 |
| Niklas, K | 1 |
| Raabe, M | 1 |
| Rössler, T | 1 |
| Seibt, B | 1 |
| Siemer, S | 1 |
| Walter, H | 1 |
| Wiedeking, B | 1 |
| Cardozo, L | 1 |
| Thorpe, A | 1 |
| Warner, J | 1 |
| Sidhu, M | 1 |
| Siegmund, W | 1 |
| Sillén, U | 2 |
| Läckgren, G | 1 |
| Schnabel, F | 3 |
| Lee, JW | 1 |
| Park, SY | 1 |
| Son, YW | 1 |
| Kim, YT | 1 |
| Krhut, J | 1 |
| Gärtner, M | 1 |
| Havránek, O | 1 |
| Nemec, D | 1 |
| Tvrdík, J | 1 |
| Baumann, I | 1 |
| Dmochowski, RR | 1 |
| Sekido, N | 1 |
| Schröder, A | 1 |
| Thüroff, JW | 1 |
| Kubota, Y | 1 |
| Kojima, Y | 1 |
| Shibata, Y | 1 |
| Imura, M | 1 |
| Kohri, K | 1 |
| Sasaki, S | 1 |
| Heine, G | 1 |
| Austin, P | 1 |
| Miller, K | 1 |
| Michael, T | 1 |
| Knispel, HH | 1 |
| Ashitomi, K | 1 |
| Yamamoto, H | 1 |
| Asimakopoulos, AD | 1 |
| Cerruto, MA | 1 |
| Del Popolo, G | 1 |
| La Martina, M | 1 |
| Artibani, W | 1 |
| Carone, R | 1 |
| Finazzi-Agrò, E | 1 |
| Leone Roberti Maggiore, U | 1 |
| Salvatore, S | 1 |
| Alessandri, F | 1 |
| Remorgida, V | 1 |
| Origoni, M | 1 |
| Candiani, M | 1 |
| Venturini, PL | 1 |
| Ferrero, S | 1 |
| McKeage, K | 1 |
| Stöhrer, M | 3 |
| Kramer, G | 3 |
| Warnack, W | 1 |
| Primus, G | 1 |
| Jinga, V | 1 |
| Manu-Marin, A | 1 |
| Calomfirescu, N | 1 |
| Grigoleit, U | 1 |
| Laschke, S | 1 |
| Schuldt, M | 1 |
| Goepel, M | 1 |
| Arnold, EP | 1 |
| Wyndaele, JJ | 1 |
| Hegde, SS | 1 |
| Jünemann, KP | 1 |
| Hessdörfer, E | 1 |
| Unamba-Oparah, I | 1 |
| Berse, M | 1 |
| Brünjes, R | 1 |
| Gramatté, T | 1 |
| Ohtake, A | 1 |
| Saitoh, C | 1 |
| Yuyama, H | 1 |
| Ukai, M | 1 |
| Okutsu, H | 1 |
| Noguchi, Y | 1 |
| Hatanaka, T | 1 |
| Suzuki, M | 1 |
| Sato, S | 1 |
| Sasamata, M | 1 |
| Miyata, K | 1 |
| Matsuyama, H | 1 |
| Shimizu, Y | 1 |
| Kamiryo, Y | 1 |
| Joko, K | 1 |
| Shimabukuro, T | 1 |
| Suga, A | 1 |
| Takemoto, M | 1 |
| Imoto, K | 1 |
| Hara, Y | 1 |
| Yamamoto, N | 1 |
| Kaneda, Y | 1 |
| Harada, N | 1 |
| Naito, K | 1 |
| Schaefer, W | 1 |
| Marui, E | 1 |
| Itoh, N | 1 |
| Yokota, T | 1 |
| Okada, H | 1 |
| Ishizuka, O | 1 |
| Ozono, S | 1 |
| Sugiyama, T | 1 |
| Miwa, Y | 1 |
| Oyama, N | 1 |
| Aoki, Y | 1 |
| Ito, H | 1 |
| Kim, SW | 1 |
| Song, SH | 1 |
| Ku, JH | 1 |
| Tasaki, S | 1 |
| Ogawa, Y | 1 |
| Maruyama, S | 1 |
| Hasuike, N | 1 |
| Yamada, S | 2 |
| Kato, K | 1 |
| Kondo, A | 1 |
| Hattori, R | 1 |
| Novara, G | 1 |
| Lazzeri, M | 1 |
| Persson de Geeter, C | 1 |
| Stehr, M | 1 |
| Radmayr, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| To Explore the Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and Develop Its Urinary Biomarker[NCT04693897] | 400 participants (Anticipated) | Observational [Patient Registry] | 2021-03-01 | Not yet recruiting | |||
| Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder: PRopiverine Study on Overactive Bladder Including Urgency Data (PROUD)[NCT00903045] | Phase 4 | 264 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Dose-Escalating Study of Propiverine Hydrochloride (Mictonetten®) in Children Suffering From Frequency-Urgency-Syndrome and Urinary Incontinence Indicative of Detrusor Overactivity (Overactive Bladder)[NCT00795925] | Phase 2 | 30 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder[NCT01640002] | Phase 1 | 42 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial[NCT00603343] | Phase 3 | 303 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for propiverine and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Humans; Mandelic Acids; Muscarinic Antagonists; Network Meta-Analy | 2018 |
Which anticholinergic is best for people with overactive bladders? A network meta-analysis.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Humans; Imidazoles; Mandelic | 2019 |
Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
Topics: Adult; Benzilates; Constipation; Humans; Imidazoles; Randomized Controlled Trials as Topic; Solifena | 2015 |
New strategies for medical management of overactive bladder in children.
Topics: Benzhydryl Compounds; Benzilates; Botulinum Toxins; Child; Cresols; Humans; Mandelic Acids; Muscarin | 2010 |
An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.
Topics: Benzilates; Drug Administration Schedule; Female; Flavoxate; Humans; Male; Mandelic Acids; Muscarini | 2012 |
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; | 2012 |
Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms.
Topics: Adolescent; Adult; Age Factors; Benzilates; Child; Child, Preschool; Drug Therapy, Combination; Fema | 2013 |
Treatment of the overactive bladder syndrome with muscarinic receptor antagonists: a matter of metabolites?
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cresols; Humans; Mandelic Acids; Muscarinic Antagonis | 2006 |
Update on drugs for overactive bladder syndrome.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Cholinergic Antagonists; Cresols; Humans; Mandelic Ac | 2007 |
22 trials available for propiverine and Urinary Bladder, Overactive
| Article | Year |
|---|---|
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.
Topics: Acetanilides; Aged; Aged, 80 and over; Benzilates; Cardiovascular Diseases; Drug Administration Sche | 2020 |
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood | 2019 |
Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Topics: Adult; Aged; Benzhydryl Compounds; Benzilates; Benzofurans; Blood Pressure; Female; Heart Rate; Huma | 2019 |
Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Double-Blind Method; Female; Humans; Male; Mandelic Acid | 2014 |
A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
Topics: Benzilates; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle | 2014 |
Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.
Topics: Benzilates; Drug Therapy, Combination; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Pros | 2014 |
Long-term efficacy of a combination therapy with an anticholinergic agent and an α1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: A randomized, prospective, comparative trial using a urody
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Benzilates; Cholinergic Antagonists; Drug Therapy, Co | 2017 |
Results of a randomized, double-blind, active-controlled clinical trial with propiverine extended release 30 mg in patients with overactive bladder.
Topics: Adolescent; Adult; Aged; Benzilates; Delayed-Action Preparations; Double-Blind Method; Female; Human | 2017 |
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzilates; Cholinergic Antagonists; Double-Blind Meth | 2009 |
Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Dose-Response Relationship, Drug; Drug Therapy, Comb | 2009 |
Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.
Topics: Adult; Aged; Benzilates; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Male; Medica | 2010 |
Pharmacokinetics and pharmacodynamics of propiverine in children aged between 5 and 10 years with symptoms of overactive bladder.
Topics: Age Factors; Benzilates; Child; Child, Preschool; Cyclic N-Oxides; Dose-Response Relationship, Drug; | 2010 |
[Combination therapy with anticholinergics and alpha-blockers for the treatment of overactive bladder in female patients--pilot study].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Benzilates; Cholinergic Antagonists; Drug Ther | 2009 |
Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study.
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Cholinergic Antagonists; Delayed-Action Preparations | 2011 |
Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzilates; Cholinergic Antagonists; Double-Blind Meth | 2011 |
Efficacy and tolerability of propiverine hydrochloride extended-release compared with immediate-release in patients with neurogenic detrusor overactivity.
Topics: Adolescent; Adult; Aged; Benzilates; Delayed-Action Preparations; Double-Blind Method; Female; Human | 2013 |
Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
Topics: Adolescent; Adult; Aged; Benzilates; Cholinergic Antagonists; Double-Blind Method; Female; Humans; M | 2007 |
Propiverine hydrochloride immediate and extended release: comparison of efficacy and tolerability in patients with overactive bladder.
Topics: Benzilates; Calcium Channel Blockers; Cholinergic Antagonists; Delayed-Action Preparations; Dose-Res | 2006 |
[Does alpha1-blocker provide additional improvement of quality-of-life in patients with overactive bladder?--a multi-center prospective randomized trial between anti-cholinergic (propiverine chloride) with and without alpha1-blocker (urapidil)].
Topics: Activities of Daily Living; Adrenergic alpha-Antagonists; Adult; Aged; Benzilates; Cholinergic Antag | 2007 |
Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
Topics: Adult; Aged; Benzilates; Constipation; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged | 2007 |
Bladder training versus combination of propiverine with bladder training for female urinary frequency. A prospective, randomized, comparative study.
Topics: Aged; Benzilates; Cholinergic Antagonists; Combined Modality Therapy; Exercise Therapy; Female; Huma | 2008 |
Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Topics: Benzilates; Child; Cholinergic Antagonists; Double-Blind Method; Female; Humans; Male; Urinary Bladd | 2009 |
27 other studies available for propiverine and Urinary Bladder, Overactive
| Article | Year |
|---|---|
What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.
Topics: Benzilates; Humans; Motivation; Nocturia; Treatment Outcome; Urinary Bladder, Overactive; Urinary In | 2022 |
Evaluation of Usefulness of Propiverine Hydrochloride in Poor Responders to Previous Anticholinergics.
Topics: Aged; Benzilates; Drug Administration Schedule; Drug Substitution; Female; Humans; Male; Medication | 2018 |
Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Benzilates; Cresols; Cross-Sectional Studies; Female; | 2014 |
Pharmacological Properties of Propiverine Contribute to Improving Lower Urinary Tract Dysfunctions in Rats with Spinal Cord Injuries.
Topics: Animals; Atropine; Benzilates; Capsaicin; Female; Muscarinic Antagonists; Rats; Spinal Cord Injuries | 2016 |
Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Epidemiologic Methods; Female; Humans; Infant; Male | 2009 |
Re: Daniela Marshall-Kehrel, Cornelia Feustel, Charlotta Persson de Geeter, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical
Topics: Adult; Benzilates; Child; Cholinergic Antagonists; Constipation; Female; Humans; Male; Urinary Bladd | 2009 |
How to manage overactive bladder in elderly individuals with dementia? A combined use of donepezil, a central acetylcholinesterase inhibitor, and propiverine, a peripheral muscarine receptor antagonist.
Topics: Aged; Aged, 80 and over; Benzilates; Chi-Square Distribution; Cholinergic Antagonists; Cholinesteras | 2009 |
[Therapy of overactive bladder with propiverine ER: results of a non-interventional study with a propiverine retard formulation and comparison to clinical studies].
Topics: Aged; Benzilates; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Male; M | 2009 |
Relationship between lower urinary tract symptoms and urinary ATP in patients with benign prostatic hyperplasia or overactive bladder.
Topics: Adenosine Triphosphate; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Animals; Benzi | 2009 |
Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Cholinergic Antagonists; Epidemiologic Methods; Fem | 2010 |
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
Topics: Benzhydryl Compounds; Benzilates; Cost-Benefit Analysis; Cresols; Decision Trees; Delayed-Action Pre | 2010 |
Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.
Topics: Adenosine Triphosphate; Animals; Benzilates; Cholinergic Antagonists; Female; Mandelic Acids; Muscar | 2010 |
Editorial comment from Dr Dmochowski to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
Topics: Benzilates; Cholinergic Antagonists; Female; Humans; Male; Urinary Bladder, Overactive | 2011 |
Editorial comment from Dr Sekido to propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
Topics: Benzilates; Cholinergic Antagonists; Female; Humans; Male; Urinary Bladder, Overactive | 2011 |
Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Female; Health Status; Humans; Japan; Male; Middle Aged; | 2011 |
Responsiveness and minimal clinically important change in overactive bladder symptom score.
Topics: Aged; Benzilates; Cholinergic Antagonists; Female; Humans; Male; Middle Aged; Quality of Life; ROC C | 2011 |
Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Cholinergic Antagonists; Cohort Studies; Cystoscopy | 2012 |
Effect of distigmine combined with propiverine on bladder activity in rats with spinal cord injury.
Topics: Animals; Benzilates; Cholinergic Antagonists; Drug Therapy, Combination; Female; Muscle Contraction; | 2012 |
Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
Topics: Adolescent; Adult; Benzilates; Child; Child, Preschool; Cholinergic Antagonists; Female; Humans; Inf | 2006 |
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
Topics: Animals; Atropine; Benzhydryl Compounds; Benzilates; Benzofurans; Binding, Competitive; Carbachol; C | 2007 |
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
Topics: Benzilates; Humans; Mandelic Acids; Parasympatholytics; Safety; Urinary Bladder, Overactive | 2007 |
Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
Topics: Administration, Intravesical; Administration, Topical; Adrenergic alpha-Antagonists; Animals; Atropi | 2007 |
Effects of propiverine and naftopidil on the urinary ATP level and bladder activity after bladder stimulation in rats.
Topics: Acetic Acid; Adenosine Triphosphate; Adrenergic alpha-Antagonists; Animals; Benzilates; Cholinergic | 2007 |
In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
Topics: Administration, Oral; Animals; Area Under Curve; Benzhydryl Compounds; Benzilates; Cholinergic Antag | 2008 |
[Efficacy and safety of propiverine on improvement of symptoms and QOL for female patients with wet overactive bladder].
Topics: Administration, Oral; Adult; Benzilates; Cholinergic Antagonists; Female; Humans; Middle Aged; Paras | 2008 |
Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Topics: Benzilates; Child; Cholinergic Antagonists; Clinical Trials, Phase III as Topic; Humans; Randomized | 2009 |
Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Topics: Benzilates; Child; Cholinergic Antagonists; Clinical Trials, Phase III as Topic; Humans; Randomized | 2009 |